AEON Biopharma, Inc.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of ga… Read more
AEON Biopharma, Inc. (AEON) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.131x
Based on the latest financial reports, AEON Biopharma, Inc. (AEON) has a cash flow conversion efficiency ratio of 0.131x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.60 Million) by net assets ($-19.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
AEON Biopharma, Inc. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how AEON Biopharma, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
AEON Biopharma, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AEON Biopharma, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BenevolentAI SA
AS:BAI
|
N/A |
|
Scandinavian Investment Group A/S
CO:SIG
|
0.032x |
|
Vince Holding Corp
NYSE:VNCE
|
0.085x |
|
Team Young Advanced Technology Co Ltd
TWO:5345
|
-0.242x |
|
Cannindah Resources Ltd
AU:CAE
|
-0.041x |
|
THUNDERFUL GROUP SK
F:8JH
|
N/A |
|
Coloray International Investment Co. Ltd
KQ:900310
|
0.003x |
|
SIMPPLE LTD. Ordinary Shares
NASDAQ:SPPL
|
-0.640x |
Annual Cash Flow Conversion Efficiency for AEON Biopharma, Inc. (2019–2024)
The table below shows the annual cash flow conversion efficiency of AEON Biopharma, Inc. from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-28.57 Million | $-20.29 Million | 0.710x | +127.30% |
| 2023-12-31 | $-153.04 Million | $-47.83 Million | 0.312x | +137.47% |
| 2022-12-31 | $-270.41 Million | $-35.58 Million | 0.132x | +3.59% |
| 2021-12-31 | $-223.82 Million | $-28.43 Million | 0.127x | +172.88% |
| 2020-12-31 | $-203.23 Million | $-9.46 Million | 0.047x | -93.14% |
| 2019-12-31 | $-65.87 Million | $-44.73 Million | 0.679x | -- |